A team from Scripps Florida and the Dana-Farber Cancer Institute has developed peroxisome proliferation-activated receptor-g-binding compounds that have potent antidiabetic activity but do not actually agonize the receptor and thus lack the side effects commonly associated with the target.1 The researchers have founded Adipothermics Inc., with backing from Third Rock Ventures, to advance the new class of compounds into the clinic.
Peroxisome proliferation-activated receptor-g (PPARG; PPARg) agonists marketed to treat type 2 diabetes include GlaxoSmithKline plc's Avandia rosiglitazone and Takeda Pharmaceutical Co. Ltd.'s Actos pioglitazone. The insulin sensitizers posted 2010 sales of $677 million and $4.7 billion, respectively.2
However, both drugs have faced regulatory scrutiny because of safety concerns. Last year, the EMA recommended suspending its approval of Avandia based on a retrospective analysis suggesting the drug increases the rate of heart attacks. This year, Takeda withdrew Actos from the French market after a